Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Frankel

Showing results (81-90 of 259) with videos related to

Pageof 26
Sort By:
Clinical Pediatrics|April 1, 1992
Compliance with breast self-examination instruction in high school studentsB A Cromer, M E Frankel, J Hayes, et al.
The Israel Medical Association Journal : IMAJ|May 22, 2022
Bioinformatic Analysis Underpinning the Frequent Occurrence of Immune Thrombocytopenic Purpura in COVID-19 PatientsArthur E Frankel, Dennis Wylie, Bjoern Peters, et al.
Expert Opinion on Biological Therapy|April 30, 2003
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemiaArthur E Frankel, Donald R Fleming, Bayard L Powell, et al.
Clinical Case Reports|June 17, 2021
Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimusArthur E Frankel, Wai C Yip, Eknath Naik, et al.
Breast Cancer Research and Treatment|January 1, 1985
Monoclonal antibodies, benign breast disease, and breast cancer. A panel discussionW L McGuire, R L Ceriani, J Schlom, et al.
Leukemia Research|September 24, 2004
The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemiaDonna E Hogge, Michaela Feuring-Buske, Brigitte Gerhard, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 21, 2009
Dissecting the urokinase activation pathway using urokinase-activated anthrax toxinShihui Liu, Thomas H Bugge, Arthur E Frankel, et al.
Bioconjugate Chemistry|July 18, 2000
In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion proteinR L Alexander, G L Kucera, B Klein, et al.
Annual Review of Medicine|January 1, 1986
Prospects for immunotoxin therapy in cancerA E Frankel, L L Houston, B F Issell, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 6, 2010
Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trialsJung Hee Woo, Yu-Jen Lee, David M Neville, et al.
Pageof 26

Showing results (81-90 of 259) with videos related to

Sort By:
Pageof 26
Clinical Pediatrics|April 1, 1992
Compliance with breast self-examination instruction in high school studentsB A Cromer, M E Frankel, J Hayes, et al.
The Israel Medical Association Journal : IMAJ|May 22, 2022
Bioinformatic Analysis Underpinning the Frequent Occurrence of Immune Thrombocytopenic Purpura in COVID-19 PatientsArthur E Frankel, Dennis Wylie, Bjoern Peters, et al.
Expert Opinion on Biological Therapy|April 30, 2003
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemiaArthur E Frankel, Donald R Fleming, Bayard L Powell, et al.
Clinical Case Reports|June 17, 2021
Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimusArthur E Frankel, Wai C Yip, Eknath Naik, et al.
Breast Cancer Research and Treatment|January 1, 1985
Monoclonal antibodies, benign breast disease, and breast cancer. A panel discussionW L McGuire, R L Ceriani, J Schlom, et al.
Leukemia Research|September 24, 2004
The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemiaDonna E Hogge, Michaela Feuring-Buske, Brigitte Gerhard, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 21, 2009
Dissecting the urokinase activation pathway using urokinase-activated anthrax toxinShihui Liu, Thomas H Bugge, Arthur E Frankel, et al.
Bioconjugate Chemistry|July 18, 2000
In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion proteinR L Alexander, G L Kucera, B Klein, et al.
Annual Review of Medicine|January 1, 1986
Prospects for immunotoxin therapy in cancerA E Frankel, L L Houston, B F Issell, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 6, 2010
Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trialsJung Hee Woo, Yu-Jen Lee, David M Neville, et al.
Pageof 26